Tainted Valsartan Alleged For Kidney Cancer Diagnosis
Tainted Valsartan Alleged For Kidney Cancer Diagnosis

Introduction
According to the latest lawsuit filed in the Superior Court of New Jersey on June 5, a woman from Tennessee has alleged Solco Healthcare, Prinston Pharmaceutical, Inc., and Huahai US, Inc. for her kidney cancer caused due to the intake of the recalled valsartan pills.
The plaintiff claims she underwent diagnosis and treatment of kidney cancer, which included the surgical removal of a tumor and a partial nephrectomy following the exposure to the pills that were recalled in recent months due to the presence of cancer-causing chemicals N-nitrosodimethylamine (NDMA) or N-Nitrosodiethylamine (NDEA). The defendants further face allegations of a manufacturing defect, strict liability, negligence, failure to warn, and loss of consortium. The plaintiff and her husband both have claimed compensatory and punitive damages.
The case joins a growing number of lawsuits pending in District Courts across the U.S. against Valsartan. Valsartan claims are consolidated under MDL No. 2875 (In re Valsartan Products Liability Litigation) in the United States District Court, District of New Jersey, presided by Judge Robert B. Kugler, U.S.D.J and Hon. Joel Schneider, U.S.M.J.
Latest News
Cencora Directors Settle Opioid Oversight Case for $111M
Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids…
Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients
A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…
FDA Adds New Warnings on Long-Term Opioid Risks
Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.
…